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Dear Editor,
In a recent review article by Trobec et al., it was stated that
therearenodataontheeffectsofACEinhibitioninthefieldof
cancer cachexia, even though there is some evidence for a
beneficial effect on muscle mass in chronic heart failure, i.e.
cardiaccachexia[1].WhileitistruethattherearenoPubMed-
listedclinicalstudies,ArkTherapeuticshascompletedaphase
III clinical trial on the use of imidapril in non-small cell lung
cancer (NSCLC), colorectal cancer and pancreatic cancer
which showed significant reduction in the rate of weight loss
in both NSCLC and colorectal cancer but not in pancreatic
cancer. However, when analyzed together, the significance on
weight loss reduction was lost and hence the trial missed its
primary endpoint [2]. These results prompted a second phase
III trial in August 2008, which was focused on NSCLC [3].
However, due to a commercial refocusing, Ark Therapeutics
is no longer pursuing this study. Furthermore, there is evidence
frompre-clinicalmodelsthatACEinhibitioncanindeedreduce
wasting of muscle mass in cancer cachexia [4]. Taken together,
there are some data—albeit limited—on the usefulness of ACE
inhibition in cancer cachexia.
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